Abstract
Galectin-3 is involved in important biological functions such as fibrogenesis and inflammation. Notably, it is associated with various diseases and plays a major role in cardiac inflammation and fibrosis. Although heart diseases are relatively common in dogs, a few studies have analyzed the circulating galectin-3 concentration in dogs with various heart diseases, including myxomatous mitral valve disease, patent ductus arteriosus, and pulmonic stenosis. The aims of the present study were to evaluate the effect of heart disease on circulating galectin-3 levels in dogs, and also to evaluate the correlation between galectin-3 concentration and conventional echocardiographic indices along with N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration in dogs with heart diseases. The medical records and archived serum samples of 107 dogs were evaluated retrospectively. In total, 107 dogs were classified into healthy dogs (n = 8), cardiac disease (n = 26), and non-cardiac disease groups (n = 73). The circulatory galectin-3 levels were analyzed using a commercially available canine-specific galectin-3 enzyme-linked immunosorbent assay kit. This study demonstrated that dogs with heart, endocrine, and dermatologic diseases had significantly higher galectin-3 levels than healthy dogs (p = 0.009, p = 0.007, and p = 0.026, respectively). Among dogs with heart diseases, dogs with concentric cardiomyopathy had significantly increased circulatory galectin-3 levels compared with healthy dogs (p = 0.028). E′/A′ had a positive association with galectin-3 levels among conventional echocardiographic indices. Moreover, the galectin-3 concentration could predict diastolic dysfunction. In dogs with myxomatous mitral valve disease, a significantly positive correlation was revealed between galectin-3 levels and NT-proBNP levels (p = 0.007). Overall, this study demonstrates that circulatory galectin-3 levels increase in dogs with heart, endocrine, and dermatologic diseases. Moreover, this study demonstrates that galectin-3 concentration could be helpful to evaluate cardiac remodeling and diastolic function. Further large-scale research is required to evaluate the role of circulating galectin-3 in dogs with heart diseases.
Highlights
Galectin-3 is a 32 to 35-kDa protein that belongs to 14 members of the β-galactoside-binding lectin family, which has important biological functions such as fibrosis formation and inflammation [1,2,3]
The major finding of this study was the elevation of serum galectin-3 concentration in dogs with heart diseases, endocrine diseases, and dermatologic diseases compared with healthy dogs
Since the type of tumor in this study was different from the previously reported tumor, it was considered that the results of galectin-3 levels in dogs with neoplasia would be different from previous results
Summary
Galectin-3 is a 32 to 35-kDa protein that belongs to 14 members of the β-galactoside-binding lectin family, which has important biological functions such as fibrosis formation and inflammation [1,2,3]. Galectin-3 was first revealed by Ho and Springer as a macrophage subpopulation specific marker and has since emerged as a novel biomarker [4]. Galectin-3 is detected in the nucleus, cytoplasm, and extracellular compartment and has been shown to participate in tissue fibrogenesis and a prognostic indicator in HF [17, 18]. It is known as a prominent prognostic biomarker for predicting the incidence of HF and cardiovascular mortality in humans [13, 19, 20]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
